Imetelstat

Drug Profile

Imetelstat

Alternative Names: GRN 140719; GRN 163; GRN 163-L; GRN 719; GRN163L peptide; Imetelstat sodium; JNJ-63935937

Latest Information Update: 02 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Geron Corporation
  • Developer Geron Corporation; Janssen Biotech
  • Class Antineoplastics; Oligonucleotides; Oligopeptides
  • Mechanism of Action Telomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Myelofibrosis; Myelodysplastic syndromes
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Myelodysplastic syndromes
  • Phase II Myelofibrosis
  • Preclinical Acute myeloid leukaemia; Chronic myeloid leukaemia
  • Suspended Multiple myeloma
  • Discontinued Breast cancer; Essential thrombocythaemia; Lymphoproliferative disorders; Non-small cell lung cancer; Polycythaemia vera; Solid tumours

Most Recent Events

  • 31 Jul 2017 Interim efficacy and adverse events data from Part 1 of the phase II/III IMerge trial in Myelodysplastic syndromes released by Geron Corporation
  • 01 Apr 2017 Adverse events and pharmacodynamics data from a preclinical study in Acute myeloid leukaemia presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)
  • 07 Dec 2016 Preclinical trials in Chronic myeloid leukaemia in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top